Sellan Pharma

Sellan Pharma is a biotechnology company focused on the discovery and development of novel small molecule therapeutics for the treatment of cancer and other life-threatening diseases. The company leverages a proprietary covalent drug discovery platform to target proteins previously considered undruggable, with a particular emphasis on high-value oncology targets like KRAS and EGFR. By utilizing advanced chemical proteomics and structural biology, Sellan aims to create highly selective and potent inhibitors that can overcome resistance mechanisms in solid tumors. Currently in the pre-clinical stage, the company is building a robust pipeline of candidates designed to provide transformative outcomes for patients with limited treatment options.